Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Oncology Reports
Erschienen in: Current Oncology Reports 10/2017

01.10.2017 | Head and Neck Cancers (EY Hanna, Section Editor)

Prognostic Stratification of Patients With Advanced Oral Cavity Squamous Cell Carcinoma

verfasst von: Dante De Paz, Huang-Kai Kao, Yenlin Huang, Kai-Ping Chang

Erschienen in: Current Oncology Reports | Ausgabe 10/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Prognosis of advanced oral squamous cell carcinoma remains a challenge for clinicians despite progress in its diagnosis and treatment over the past decades. In this review, we assessed clinicopathological factors and potential biomarkers along with their prognostic relevance in an attempt to develop optimal treatment strategies for these patients.

Recent Findings

In addition to several pathologic factors that have been proposed to improve prognostic stratification and treatment planning in the eighth edition of the American Joint Committee staging manual on cancer, we reviewed some other imaging and clinicopathological parameters demonstrated to be closely associated with patient prognosis, along with the biomarkers related to novel target or immune therapy.

Summary

Evaluation of current literature regarding the prognostic stratification used in contemporary clinicopathological studies and progress in the development of targeted or immune therapy may help these patients benefit from tailored and personalized treatment and obtain better oncological results.
Literatur
1.
Marur S, Forastiere AA. Head and neck cancer: changing epidemiology, diagnosis, and treatment. Mayo Clin Proc. 2008;83(4):489–501.CrossRefPubMed
2.
Murthy V, Agarwal J, Laskar S, Gupta T, Budrukkar A, Pai P, et al. Analysis of prognostic factors in 1180 patients with oral cavity primary cancer treated with definitive or adjuvant radiotherapy. J Cancer Res Ther. 2010;6(3):282–9.CrossRefPubMed
3.
Gallo O, Bianchi S, Porfirio B. Bcl-2 overexpression and smoking history in head and neck cancer. JNCI: Journal of the National Cancer Institute. 1995;87(13):1024–5.CrossRefPubMed
4.
Deleyiannis FWB, Thomas DB, Vaughan TL, Davis S. Alcoholism: independent predictor of survival in patients with head and neck cancer. JNCI: Journal of the National Cancer Institute. 1996;88(8):542–9.CrossRefPubMed
5.
Dave BJ, Trivedi AH, Adhvaryu SG. Role of areca nut consumption in the cause of oral cancers. A cytogenetic assessment. Cancer. 1992;70(5):1017–23.CrossRefPubMed
6.
7.
Chiang CJ, Chen YC, Chen CJ, You SL, Lai MS. Cancer trends in Taiwan. Jpn J Clin Oncol. 2010;40(10):897–904.CrossRefPubMed
8.
Lin WJ, Jiang RS, Wu SH, Chen FJ, Liu SA. Smoking, alcohol, and betel quid and oral cancer: a prospective cohort study. Journal of oncology. 2011;2011:525976.CrossRefPubMedPubMedCentral
9.
Liao CT, Wang HM, Ng SH, Yen TC, Lee LY, Hsueh C, et al. Good tumor control and survivals of squamous cell carcinoma of buccal mucosa treated with radical surgery with or without neck dissection in Taiwan. Oral Oncol. 2006;42(8):800–9.CrossRefPubMed
10.
Jeng JH, Chang MC, Hahn LJ. Role of areca nut in betel quid-associated chemical carcinogenesis: current awareness and future perspectives. Oral Oncol. 2001;37(6):477–92.CrossRefPubMed
11.
Hunter KD, Parkinson EK, Harrison PR. Profiling early head and neck cancer. Nat Rev Cancer. 2005;5(2):127–35.CrossRefPubMed
12.
Braakhuis BJ, Leemans CR, Brakenhoff RH. Expanding fields of genetically altered cells in head and neck squamous carcinogenesis. Semin Cancer Biol. 2005;15(2):113–20.CrossRefPubMed
13.
Liu FY, Liao CT, Yen TC. Synchronous malignancies in patients with squamous cell carcinomas of the oral cavity. Eur J Nucl Med Mol Imaging. 2011;38(6):1020–8.CrossRefPubMed
14.
Kao HK, Abdelrahman M, Huang Y, Tsai CH, Barrera MJ, Tsang NM, et al. Multiple concomitant oral cavity cancers: incidence, management, and outcomes. J Surg Oncol. 2017;115(7):835-41
15.
Kao HK, Guo LF, Cheng MH, Chen IH, Liao CT, Fang KH, et al. Predicting postoperative morbidity and mortality by model for endstage liver disease score for patients with head and neck cancer and liver cirrhosis. Head & neck. 2011;33(4):529–34.CrossRef
16.
Liao CT, Kang CJ, Lee LY, Hsueh C, Lin CY, Fan KH, et al. Association between multidisciplinary team care approach and survival rates in patients with oral cavity squamous cell carcinoma. Head & neck. 2016;38(Suppl 1):E1544–53.CrossRef
17.
18.
Arya S, Rane P, Deshmukh A. Oral cavity squamous cell carcinoma: role of pretreatment imaging and its influence on management. Clin Radiol. 2014;69(9):916–30.CrossRefPubMed
19.
Mukherji SK, Isaacs DL, Creager A, Shockley W, Weissler M, Armao D. CT detection of mandibular invasion by squamous cell carcinoma of the oral cavity. AJR Am J Roentgenol. 2001;177(1):237–43.CrossRefPubMed
20.
Brockenbrough JM, Petruzzelli GJ, Lomasney L. DentaScan as an accurate method of predicting mandibular invasion in patients with squamous cell carcinoma of the oral cavity. Archives of otolaryngology--head & neck surgery. 2003;129(1):113–7.CrossRef
21.
Curtin HD, Ishwaran H, Mancuso AA, Dalley RW, Caudry DJ, McNeil BJ. Comparison of CT and MR imaging in staging of neck metastases. Radiology. 1998;207(1):123–30.CrossRefPubMed
22.
Ng SH, Ko SF, Toh CH, Chen YL. Imaging of neck metastases. Chang Gung Med J. 2006;29(2):119–29.PubMed
23.
Huang SH, Hwang D, Lockwood G, Goldstein DP, O'Sullivan B. Predictive value of tumor thickness for cervical lymph-node involvement in squamous cell carcinoma of the oral cavity: a meta-analysis of reported studies. Cancer. 2009;115(7):1489–97.CrossRefPubMed
24.
Prabhu RS, Magliocca KR, Hanasoge S, Aiken AH, Hudgins PA, Hall WA, et al. Accuracy of computed tomography for predicting pathologic nodal extracapsular extension in patients with head-and-neck cancer undergoing initial surgical resection. Int J Radiat Oncol Biol Phys. 2014;88(1):122–9.CrossRefPubMed
25.
Crecco M, Vidiri A, Angelone ML, Palma O, Morello R. Retromolar trigone tumors: evaluation by magnetic resonance imaging and correlation with pathological data. Eur J Radiol. 1999;32(3):182–8.CrossRefPubMed
26.
Pfister DG, Spencer S, Brizel DM, Burtness B, Busse PM, Caudell JJ, et al. Head and neck cancers, version 2.2014. Clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2014;12(10):1454–87.CrossRefPubMed
27.
Liao CT, Ng SH, Chang JT, Wang HM, Hsueh C, Lee LY, et al. T4b oral cavity cancer below the mandibular notch is resectable with a favorable outcome. Oral Oncol. 2007;43(6):570–9.CrossRefPubMed
28.
Ong CK, Chong VF. Imaging of perineural spread in head and neck tumours. Cancer imaging : the official publication of the International Cancer Imaging Society. 2010;10 Spec no A:S92–8.
29.
Ginsberg LE, DeMonte F. Imaging of perineural tumor spread from palatal carcinoma. AJNR Am J Neuroradiol. 1998;19(8):1417–22.PubMed
30.
Liao CT, Wang HM, Chang JT, Lin CY, Ng SH, Huang SF, et al. Influence of pathological nodal status and maximal standardized uptake value of the primary tumor and regional lymph nodes on treatment plans in patients with advanced oral cavity squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2010;77(2):421–9.CrossRefPubMed
31.
Coca-Pelaz A, Rodrigo JP, Suarez C. Clinicopathologic analysis and predictive factors for distant metastases in patients with head and neck squamous cell carcinomas. Head & neck. 2012;34(6):771–5.CrossRef
32.
Krabbe CA, Pruim J, van der Laan BF, Rodiger LA, Roodenburg JL. FDG-PET and detection of distant metastases and simultaneous tumors in head and neck squamous cell carcinoma: a comparison with chest radiography and chest CT. Oral Oncol. 2009;45(3):234–40.CrossRefPubMed
33.
34.
Groome PA, Schulze K, Boysen M, Hall SF, Mackillop WJ. A comparison of published head and neck stage groupings in carcinomas of the oral cavity. Head & neck. 2001;23(8):613–24.CrossRef
35.
Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual. 7th ed. New York: NS; 2010.
36.
Amin MB, Edge S, Green FL, et al., editors. AJCC cancer staging manual. 8th ed. New York: Springer; 2017.
37.
Greene FL, Page DL, Fleming ID, et al., editors. AJCC cancer staging manual. 6th ed. New York: Springer; 2002.
38.
Fleming ID, Cooper JS, Henson DE, RVP H, Kennedy BJ, Murphy GP, et al., editors. AJCC cancer staging manual. 5th ed. Philadelphia: Lippincott-Raven; 1997.
39.
•• Ebrahimi A, Gil Z, Amit M, Yen TC, Liao CT, Chaturvedi P, et al. Primary tumor staging for oral cancer and a proposed modification incorporating depth of invasion: an international multicenter retrospective study. JAMA otolaryngology-- head & neck surgery. 2014;140(12):1138–48. Optimal cutoff points of 5 mm in T1 and 10 mm in T2-4 category disease were used to develop a modified T staging system that was preferred to the AJCC system on the basis of lower AIC, visual inspection of Kaplan-Meier curves, and significant improvement in bootstrapped C-index. CrossRef
40.
•• Lydiatt WM, Patel SG, O'Sullivan B, Brandwein MS, Ridge JA, Migliacci JC, et al. Head and neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(2):122–37. The recently released eighth edition of the American Joint Committee on Cancer (AJCC) Staging Manual, Head and Neck Section, introduces significant modifications from the prior seventh edition. This article detailed several of the most significant modifications and the rationale for the revisions of this staging manual. CrossRefPubMed
41.
Spiro RH, Huvos AG, Wong GY, Spiro JD, Gnecco CA, Strong EW. Predictive value of tumor thickness in squamous carcinoma confined to the tongue and floor of the mouth. Am J Surg. 1986;152(4):345–50.CrossRefPubMed
42.
Shim SJ, Cha J, Koom WS, Kim GE, Lee CG, Choi EC, et al. Clinical outcomes for T1-2N0-1 oral tongue cancer patients underwent surgery with and without postoperative radiotherapy. Radiation oncology (London, England). 2010;5:43.CrossRef
43.
Liao CT, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY, et al. Does adjuvant radiation therapy improve outcomes in pT1-3N0 oral cavity cancer with tumor-free margins and perineural invasion? Int J Radiat Oncol Biol Phys. 2008;71(2):371–6.CrossRefPubMed
44.
Sparano A, Weinstein G, Chalian A, Yodul M, Weber R. Multivariate predictors of occult neck metastasis in early oral tongue cancer. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery. 2004;131(4):472–6.CrossRef
45.
Kane SV, Gupta M, Kakade AC, DC A. Depth of invasion is the most significant histological predictor of subclinical cervical lymph node metastasis in early squamous carcinomas of the oral cavity. European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2006;32(7):795–803.CrossRef
46.
Clark JR, Naranjo N, Franklin JH, de Almeida J, Gullane PJ. Established prognostic variables in N0 oral carcinoma. Otolaryngology--head and neck surgery: official journal of American Academy of Otolaryngology-Head and Neck Surgery. 2006;135(5):748–53.CrossRef
47.
Ganly I, Goldstein D, Carlson DL, Patel SG, O'Sullivan B, Lee N, et al. Long-term regional control and survival in patients with “low-risk,” early stage oral tongue cancer managed by partial glossectomy and neck dissection without postoperative radiation: the importance of tumor thickness. Cancer. 2013;119(6):1168–76.CrossRefPubMed
48.
Kang CJ, Lin CY, Wang HM, Fan KH, Ng SH, Lee LY, et al. The number of pathologically positive lymph nodes and pathological tumor depth predicts prognosis in patients with poorly differentiated squamous cell carcinoma of the oral cavity. Int J Radiat Oncol Biol Phys. 2011;81(4):e223–30.CrossRefPubMed
49.
Piazza C, Montalto N, Paderno A, Taglietti V, Nicolai P. Is it time to incorporate ‘depth of infiltration’ in the T staging of oral tongue and floor of mouth cancer? Current opinion in otolaryngology & head and neck surgery. 2014;22(2):81–9.CrossRef
50.
Patel SG, Lydiatt WM. Staging of head and neck cancers: is it time to change the balance between the ideal and the practical? J Surg Oncol. 2008;97(8):653–7.CrossRefPubMed
51.
Mamelle G, Pampurik J, Luboinski B, Lancar R, Lusinchi A, Bosq J. Lymph node prognostic factors in head and neck squamous cell carcinomas. Am J Surg. 1994;168(5):494–8.CrossRefPubMed
52.
van den Brekel MW, Lodder WL, Stel HV, Bloemena E, Leemans CR, van der Waal I. Observer variation in the histopathologic assessment of extranodal tumor spread in lymph node metastases in the neck. Head & neck. 2012;34(6):840–5.CrossRef
53.
Yamada S, Yanamoto S, Otani S, Hasegawa T, Miyakoshi M, Minamikawa T, et al. Evaluation of the level of progression of extracapsular spread for cervical lymph node metastasis in oral squamous cell carcinoma. Int J Oral Maxillofac Surg. 2016;45(2):141–6.CrossRefPubMed
54.
•• Wreesmann VB, Katabi N, Palmer FL, Montero PH, Migliacci JC, Gonen M, et al. Influence of extracapsular nodal spread extent on prognosis of oral squamous cell carcinoma. Head & neck. 2016;38(Suppl 1):E1192–9. This article described that ECS is clinically relevant to treatment outcome and survival in oral cavity SCC when it has extended more than 1.7 mm beyond the nodal capsule. CrossRef
55.
Bennett SH, Futrell JW, Roth JA, Hoye RC, Ketcham AS. Prognostic significance of histologic host response in cancer of the larynx or hypopharynx. Cancer. 1971;28(5):1255–65.CrossRefPubMed
56.
Snow GB, Annyas AA, van Slooten EA, Bartelink H, Hart AA. Prognostic factors of neck node metastasis. Clinical otolaryngology and allied sciences. 1982;7(3):185–92.CrossRefPubMed
57.
Sessions DG. Surgical pathology of cancer of the larynx and hypopharynx. Laryngoscope. 1976;86(6):814–39.CrossRefPubMed
58.
Johnson JT, Barnes EL, Myers EN, Schramm VL Jr, Borochovitz D, Sigler BA. The extracapsular spread of tumors in cervical node metastasis. Archives of otolaryngology (Chicago, Ill: 1960). 1981;107(12):725–9.CrossRef
59.
Myers JN, Greenberg JS, Mo V, Roberts D. Extracapsular spread. A significant predictor of treatment failure in patients with squamous cell carcinoma of the tongue. Cancer. 2001;92(12):3030–6.CrossRefPubMed
60.
61.
Manikantan K, Sayed SI, Syrigos KN, Rhys-Evans P, Nutting CM, Harrington KJ, et al. Challenges for the future modifications of the TNM staging system for head and neck cancer: case for a new computational model? Cancer Treat Rev. 2009;35(7):639–44.CrossRefPubMed
62.
Ballantyne AJ, McCarten AB, Ibanez ML. The extension of cancer of the head and neck through peripheral nerves. Am J Surg. 1963;106:651–67.CrossRefPubMed
63.
Fagan JJ, Collins B, Barnes L, D'Amico F, Myers EN, Johnson JT. Perineural invasion in squamous cell carcinoma of the head and neck. Archives of otolaryngology--head & neck surgery. 1998;124(6):637–40.CrossRef
64.
Garzino-Demo P, Dell'Acqua A, Dalmasso P, Fasolis M, La Terra Maggiore GM, Ramieri G, et al. Clinicopathological parameters and outcome of 245 patients operated for oral squamous cell carcinoma. Journal of cranio-maxillo-facial surgery: official publication of the European Association for Cranio-Maxillo-Facial Surgery. 2006;34(6):344–50.CrossRef
65.
Rahima B, Shingaki S, Nagata M, Saito C. Prognostic significance of perineural invasion in oral and oropharyngeal carcinoma. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics. 2004;97(4):423–31.CrossRefPubMed
66.
Brown B, Barnes L, Mazariegos J, Taylor F, Johnson J, Wagner RL. Prognostic factors in mobile tongue and floor of mouth carcinoma. Cancer. 1989;64(6):1195–202.CrossRefPubMed
67.
Yang TL, Wang CP, Ko JY, Lin CF, Lou PJ. Association of tumor satellite distance with prognosis and contralateral neck recurrence of tongue squamous cell carcinoma. Head & neck. 2008;30(5):631–8.CrossRef
68.
Yang TL, Wu CT, Ko JY, Wang CP, Lou PJ, Chang YL. Significance of tumor satellite variables in reflecting the epithelial-mesenchymal transition of tongue cancer. Oral Oncol. 2011;47(8):720–4.CrossRefPubMed
69.
Oliver AJ, Helfrick JF, Gard D. Primary oral squamous cell carcinoma: a review of 92 cases. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons. 1996;54(8):949–954; discussion 55.
70.
Barnes L EJ, et al. Pathology and genetics of head and neck tumours. World Health Organization Classification of Tumours. 1 st ed. IARC L, editor 2015.
71.
Effiom OA, Adeyemo WL, Omitola OG, Ajayi OF, Emmanuel MM, Gbotolorun OM. Oral squamous cell carcinoma: a clinicopathologic review of 233 cases in Lagos, Nigeria. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons. 2008;66(8):1595–9.CrossRef
72.
Fang KH, Kao HK, Cheng MH, Chang YL, Tsang NM, Huang YC, et al. Histological differentiation of primary oral squamous cell carcinomas in an area of betel quid chewing prevalence. Otolaryngology--head and neck surgery: official journal of American Academy of Otolaryngology-Head and Neck Surgery. 2009;141(6):743–9.CrossRef
73.
Woolgar JA, Rogers S, West CR, Errington RD, Brown JS, Vaughan ED. Survival and patterns of recurrence in 200 oral cancer patients treated by radical surgery and neck dissection. Oral Oncol. 1999;35(3):257–65.CrossRefPubMed
74.
Close LG, Brown PM, Vuitch MF, Reisch J, Schaefer SD. Microvascular invasion and survival in cancer of the oral cavity and oropharynx. Archives of otolaryngology--head & neck surgery. 1989;115(11):1304–9.CrossRef
75.
Magnano M, Bongioannini G, Lerda W, Canale G, Tondolo E, Bona M, et al. Lymph node metastasis in head and neck squamous cells carcinoma: multivariate analysis of prognostic variables. Journal of experimental & clinical cancer research: CR. 1999;18(1):79–83.
76.
Adel M, Kao HK, Hsu CL, Huang JJ, Lee LY, Huang Y, et al. Evaluation of lymphatic and vascular invasion in relation to clinicopathological factors and treatment outcome in oral cavity squamous cell carcinoma. Medicine. 2015;94(43):e1510.CrossRefPubMedPubMedCentral
77.
Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517(7536):576–82.
78.
Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (New York, NY). 2011;333(6046):1154–7.CrossRef
79.
Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, et al. The mutational landscape of head and neck squamous cell carcinoma. Science (New York, NY). 2011;333(6046):1157–60.CrossRef
80.
Zhou G, Liu Z, Myers JN. TP53 mutations in head and neck squamous cell carcinoma and their impact on disease progression and treatment response. J Cell Biochem. 2016;117(12):2682–92.CrossRefPubMed
81.
Chang KP, Chang YT, Liao CT, Yen TC, Chen IH, Chang YL, et al. Prognostic cytokine markers in peripheral blood for oral cavity squamous cell carcinoma identified by multiplexed immunobead-based profiling. Clinica chimica acta; international journal of clinical chemistry. 2011;412(11–12):980–7.CrossRefPubMed
82.
Chang KP, Kao HK, Wu CC, Fang KH, Chang YL, Huang YC, et al. Pretreatment interleukin-6 serum levels are associated with patient survival for oral cavity squamous cell carcinoma. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery. 2013;148(5):786–91.CrossRef
83.
Chang KP, Wu CC, Fang KH, Tsai CY, Chang YL, Liu SC, et al. Serum levels of chemokine (C-X-C motif) ligand 9 (CXCL9) are associated with tumor progression and treatment outcome in patients with oral cavity squamous cell carcinoma. Oral Oncol. 2013;49(8):802–7.CrossRefPubMed
84.
Chang KP, Yu JS, Chien KY, Lee CW, Liang Y, Liao CT, et al. Identification of PRDX4 and P4HA2 as metastasis-associated proteins in oral cavity squamous cell carcinoma by comparative tissue proteomics of microdissected specimens using iTRAQ technology. J Proteome Res. 2011;10(11):4935–47.CrossRefPubMed
85.
Kato Y, Uzawa K, Saito K, Nakashima D, Kato M, Nimura Y, et al. Gene expression pattern in oral cancer cervical lymph node metastasis. Oncol Rep. 2006;16(5):1009–14.PubMed
86.
Nguyen ST, Hasegawa S, Tsuda H, Tomioka H, Ushijima M, Noda M, et al. Identification of a predictive gene expression signature of cervical lymph node metastasis in oral squamous cell carcinoma. Cancer Sci. 2007;98(5):740–6.CrossRefPubMed
87.
Chang KP, Kao HK, Yen TC, Chang YL, Liang Y, Liu SC, et al. Overexpression of macrophage inflammatory protein-3alpha in oral cavity squamous cell carcinoma is associated with nodal metastasis. Oral Oncol. 2011;47(2):108–13.CrossRefPubMed
88.
Fang KH, Kao HK, Chi LM, Liang Y, Liu SC, Hseuh C, et al. Overexpression of BST2 is associated with nodal metastasis and poorer prognosis in oral cavity cancer. Laryngoscope. 2014;124(9):E354–60.CrossRefPubMed
89.
Chang KP, Wang CL, Kao HK, Liang Y, Liu SC, Huang LL, et al. Overexpression of caldesmon is associated with lymph node metastasis and poorer prognosis in patients with oral cavity squamous cell carcinoma. Cancer. 2013;119(22):4003–11.CrossRefPubMed
90.
Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567–78.CrossRefPubMed
91.
Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(27):2940–50.CrossRef
92.
Martins RG, Parvathaneni U, Bauman JE, Sharma AK, Raez LE, Papagikos MA, et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(11):1415–21.CrossRef
93.
Bauman JE, Duvvuri U, Gooding WE, Rath TJ, Gross ND, Song J, et al. Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer. JCI insight. 2017;2(6):e90449.CrossRefPubMedPubMedCentral
94.
Lin YM, Sung WW, Hsieh MJ, Tsai SC, Lai HW, Yang SM, et al. High PD-L1 expression correlates with metastasis and poor prognosis in oral squamous cell carcinoma. PLoS One. 2015;10(11):e0142656.CrossRefPubMedPubMedCentral
95.
Satgunaseelan L, Gupta R, Madore J, Chia N, Lum T, Palme CE, et al. Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype. Pathology. 2016;48(6):574–80.CrossRefPubMed
96.
Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4(127):127ra37.CrossRefPubMedPubMedCentral
97.
Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856–67.CrossRefPubMed
98.
Rebelatto MC, Midha A, Mistry A, Sabalos C, Schechter N, Li X, et al. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma. Diagnostic pathology. 2016;11(1):95.
Metadaten
Titel
Prognostic Stratification of Patients With Advanced Oral Cavity Squamous Cell Carcinoma
verfasst von
Dante De Paz
Huang-Kai Kao
Yenlin Huang
Kai-Ping Chang
Publikationsdatum
01.10.2017
Verlag
Springer US
Erschienen in
Current Oncology Reports / Ausgabe 10/2017
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-017-0624-3

Weitere Artikel der Ausgabe 10/2017

Current Oncology Reports 10/2017 Zur Ausgabe

Cardio-oncology (EH Yang, Section Editor)

Cardiac Imaging: Multimodality Advances and Surveillance Strategies in Detection of Cardiotoxicity

Breast Cancer (B Overmoyer, Section Editor)

Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1

Integrative Care (C Lammersfeld, Section Editor)

Mind-Body Therapies in Cancer: What Is the Latest Evidence?

Evolving Therapies (R Bukowski, Section Editor)

Cancer Clonal Theory, Immune Escape, and Their Evolving Roles in Cancer Multi-Agent Therapeutics

Geriatric Oncology (AR MacKenzie, Section Editor)

Motivating Older Adults with Cancer to Keep Moving: the Implications of Lifestyle Interventions on Physical Activity

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise